Gastrointestinale Stromatumoren (GIST)
Author:
Publisher
Elsevier
Reference29 articles.
1. Blay JY, Shen L, Kang Y-K et al.: Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 16(5) (2015) 550–560. doi: 10.1016/S1470-2045(15)70105-1. Epub 2015 Apr 14.
2. Blay JY, Serrano C, Heinrich MC et al.: Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(7) (2020) 923–934. doi: 10.1016/S1470-2045(20)30168-6. Epub 2020 Jun 5. Erratum in: Lancet Oncol 21(7) (2020) e341. PMID: 32511981.
3. Bouchet S, Poulette S, Titier K et al.: Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer 57 (2016) 31–38. doi: 10.1016/j.ejca.2015.12.029. Epub 2016 Feb 4. PMID: 26851399.
4. Catena F, Di Battista M, Ansaloni L et al.: GISTologist Study Group: Microscopic margins of resection influence primary gastrointestinal stromal tumor survival. Onkologie 35(11) (2012) 645–648.
5. Emile JF, Brahimi S, Coindre JM et al.: Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol Sep; 29(3) (2012) 1765–1772. doi: 10.1007/s12032-011-0074-y. Epub 2011 Sep 28. PMID: 21953054.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3